BMCS continues to add digital assets to its balance sheet

WOODLAND HILLS, CA / ACCESSWIRE / December 28, 2021 /BMCS SUMCOIN INDICATIVE FUND, INC doing business like BioTech Medics, Inc. (OTC PINK:BMCS) continues to execute its business plan by increasing its balance sheet with digital assets. To date on Company balance includes over $ 75 million in assets.

According to Anthony K. Miller, CEO, “BMCS Sumcoin Index Fund Inc., formerly BioTech Medics, Inc., has a Delaware statutory trust that holds Sumcoin (SUM) on behalf of its shareholders. The investment objective of the trust company is that the shares reflect the value of the Sums held by the Trust, determined by the value of the Sumcoin index, less the expenses and other liabilities of the Trust, divided by the I / O stock (the total net asset value, to date, is $ 0.38 and our balance sheet now totals $ 75.9 million of Sumcoin). The current value of our stock does not reflect this capital structure (the expected P / E ratio) … and we hope that in the coming weeks , our true value will be realized.

Sumcoin is the “First indexed coin in the world” it’s a crypto blockchain that uses a scrypt proof-of-work algorithm to determine its value (which changes every 20 minutes). People looking to invest in digital (crypto) assets can invest in our stocks and benefit from the appreciation in the value of the company’s shares which is designed to appreciate faster than digital currency.

BMCS has a fascinating business model which is modeled after other successful companies in this Digital asset market. Our goal is to make Sumcoin as liquid as other currencies in this digital ecosystem. We have filed a Reg. Offer D 506c with the SEC and we started raising capital with that exemption. The capital raised announces on our balance sheet, also increases the value of our share.

Today we remain in a smooth launch of our business plan and in the coming weeks we will have a more robust project launch at a wider target audience of digital asset investors. I invite you all to visit our website at better understand our mission and our business model; commented Miller “


Forward-looking statements: This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including those regarding expected plans of BioTech Medics, Inc., and related companies. All statements included in this press release, other than statements of historical fact, are forward-looking statements. Forward-looking statements involve risks, assumptions, uncertainties and other known and unknown factors. Future statements and statements using words such as “may,“ may ”,“ could ”,“ should ”,“ foresee ”,“ aim ”,“. intend ” objective ‘,’ estimate ‘,’ ” ‘) Forward-looking statements are not a guarantee of performance and are subject to a number of risks and uncertainties, many of which are difficult to predict and beyond of our control.

These risks and uncertainties could cause actual results to differ materially from those expressed or implied by forward-looking statements, and therefore should be carefully considered. You should take into account the risk areas described in any forward-looking statements that may be made in this document. We caution you not to place undue reliance on forward-looking statements, which speak only as of the date of this report, and readers should carefully consider this report in its entirety. We disclaim any obligation to update any of these forward-looking statements as a result of new information, future events or otherwise, except as expressly required by law. Further information on our risk factors is contained in our filings with the OTC markets and the SEC website. Any forward-looking statements we make here speak only as of the date on which they are made. Factors or events that could cause our actual results to vary may occur from time to time, and we cannot predict all of them. We assume no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.


EMAIL: [email protected]
PHONE: 800.988.3782

THE SOURCE: BioTech Medics Inc

See the source version on

Source link

Previous Gap (NYSE: GPS) has a somewhat strained record
Next BMCS Continues To Add Digital Assets To Its Balance Sheet | 2021-12-28 | Press Releases